The recombinant human interferon alpha-2b (IFN-a2b) nasal drop formulation (Nasalferon)
was studied as prophylaxis for SARS-CoV-2. Healthy volunteers between 19 and 80 years …

ObjectiveTo investigate the efficacy and safety of recombinant human interferon alpha
(rhIFN-) nasal drops in healthy medical staff to prevent coronavirus disease 2019 (COVID …

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), known as
Coronavirus disease-2019 (COVID-19), has caused the sixth world's public health …

The SARS–CoV-2 infection has caused both acute and chronic COVID–19 disease during
the recent pandemic with emerging more transmissible SARS–CoV–2 Omicron variants …

INTRODUCTION: The pandemic spread of a new coronavirus infection, COVID-19, has
caused a global emergency and attracted the attention of public health professionals and …

In addition to SARS-CoV-2 and its variants, emerging viruses that cause respiratory viral
infections will continue to arise. Increasing evidence suggests a delayed, possibly …

Background: To date, there is no evidence supporting the effectiveness of the use of any
drugs for the prevention of COVID-19. However, we have a number of promising drugs at …

Although the subject of intensive preclinical and clinical research, controversy on the
protective vs. deleterious effect of interferon (IFN) in COVID-19 remains. Some apparently …

Impaired type I interferons (IFNs) production or signaling have been associated with severe
COVID-19, further promoting the evaluation of recombinant type I IFNs as therapeutics …

The nasal epithelium is a plausible entry point for SARS-CoV-2, a site of pathogenesis and
transmission, and may initiate the host response to SARS-CoV-2. Antiviral interferon (IFN) …